Trials / Active Not Recruiting
Active Not RecruitingNCT04472910
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma: A Multicentre Canadian Phase II Study
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To date, there have been no Canadian led neoadjuvant or peri-operative trials, this multicentre design gives the opportunity to build more experience with this strategy across Canada in more institutions. The design of this prospective trial will also test our important hypotheses regarding the use of biomarkers to understand the benefit of mFFX in improving outcomes for patients with resectable pancreas cancer. Data from this study would likely inform future studies where patients are given personalised options for the best treatment strategies rather than one empiric approach.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Modified Folforinox (mFFX) | Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy |
Timeline
- Start date
- 2020-08-21
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
- First posted
- 2020-07-16
- Last updated
- 2026-03-12
Locations
8 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT04472910. Inclusion in this directory is not an endorsement.